ATE187330T1 - Verwendung von 3,4-diphenyl chroman derivaten zur herstellung eines medikaments zur absinkung des cholesterolspiegels - Google Patents

Verwendung von 3,4-diphenyl chroman derivaten zur herstellung eines medikaments zur absinkung des cholesterolspiegels

Info

Publication number
ATE187330T1
ATE187330T1 AT95300902T AT95300902T ATE187330T1 AT E187330 T1 ATE187330 T1 AT E187330T1 AT 95300902 T AT95300902 T AT 95300902T AT 95300902 T AT95300902 T AT 95300902T AT E187330 T1 ATE187330 T1 AT E187330T1
Authority
AT
Austria
Prior art keywords
diphenyl
medication
produce
cholesterol levels
lowering cholesterol
Prior art date
Application number
AT95300902T
Other languages
English (en)
Inventor
Henry Uhlman Bryant
Jeffrey Alan Dodge
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE187330T1 publication Critical patent/ATE187330T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT95300902T 1994-02-18 1995-02-14 Verwendung von 3,4-diphenyl chroman derivaten zur herstellung eines medikaments zur absinkung des cholesterolspiegels ATE187330T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/198,456 US5407955A (en) 1994-02-18 1994-02-18 Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Publications (1)

Publication Number Publication Date
ATE187330T1 true ATE187330T1 (de) 1999-12-15

Family

ID=22733460

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95300902T ATE187330T1 (de) 1994-02-18 1995-02-14 Verwendung von 3,4-diphenyl chroman derivaten zur herstellung eines medikaments zur absinkung des cholesterolspiegels

Country Status (10)

Country Link
US (10) US5407955A (de)
EP (2) EP0976398A3 (de)
JP (1) JPH07258080A (de)
AT (1) ATE187330T1 (de)
CA (1) CA2142513A1 (de)
DE (1) DE69513708T2 (de)
DK (1) DK0672412T3 (de)
ES (1) ES2140618T3 (de)
GR (1) GR3032813T3 (de)
PT (1) PT672412E (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
CA2162586C (en) 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
US5981470A (en) * 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
PT769956E (pt) * 1994-07-22 2000-07-31 Hampton Roads Medical College Utilizacao de antagonistas de gnrh para a preparacao de medicamentos para o tratamento de condicoes dependentes de gonado-esteroides
US5484798A (en) * 1994-09-20 1996-01-16 Eli Lilly And Company Benzothiopene compounds, compositions, and method of inhibiting restenosis
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
HUP9800521A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or propylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis
HUP9702244A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US6451817B1 (en) * 1995-03-10 2002-09-17 Eli Lilly And Company Alpha-substituted-1-benzyl-napthyls
US6384053B1 (en) * 1995-03-10 2002-05-07 Eli Lilly And Company α-substituted-1-benzyl-napthyls
US6444688B1 (en) * 1995-06-07 2002-09-03 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6110099A (en) * 1995-11-13 2000-08-29 Benderev; Theodore V. Devices and methods for assessment and treatment of urinary and fecal incontinence
US5883118A (en) * 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
CA2253673C (en) 1996-05-01 2009-09-08 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
ATE262516T1 (de) * 1996-05-08 2004-04-15 Novo Nordisk As Kristallines (-)-3r,4r-trans-7-methoxy-2,2-
US5756539A (en) * 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5780502A (en) * 1996-07-12 1998-07-14 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
AU5049098A (en) * 1996-11-28 1998-06-22 Novo Nordisk A/S Pharmaceutical formulation
US5977158A (en) * 1996-11-28 1999-11-02 Novo Nordisk A/S Pharmaceutical formulations comprising levormeloxifene compounds
DE69807200D1 (de) * 1997-02-27 2002-09-19 Novo Nordisk As Inklusionskomplexe in waessriger loesung
AU7906498A (en) * 1997-06-12 1998-12-30 Novo Nordisk A/S Cristalline ( - ) - 3r,4r -trans-7-methoxy -2,2-dimethyl-3-phenyl-4- {4-{2-(pyrrolidin-1-yl)ethoxy} phenyl}chromane, hydrogen maleate
US6372776B2 (en) * 1997-06-12 2002-04-16 Novo Nordisk A/S Crystalline(−)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane, hydrogen maleate
WO1999024032A1 (en) * 1997-11-10 1999-05-20 Novo Nordisk A/S Transdermal delivery of 3,4-diarylchromans
AU3023999A (en) * 1998-03-20 1999-10-18 Novo Nordisk A/S Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for lowering plasma levels of lp(a) in a human or sub-human primate
US6525084B2 (en) * 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
ATE529419T1 (de) * 2000-03-01 2011-11-15 Organon Nv Chromanderivate als estrogene verbindungen
TWI303990B (en) * 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
US7098292B2 (en) * 2003-05-08 2006-08-29 The Procter & Gamble Company Molded or extruded articles comprising polyhydroxyalkanoate copolymer and an environmentally degradable thermoplastic polymer
DE102008043992B4 (de) * 2008-11-21 2012-04-05 Schott Ag Transparente Reaktivpanzerung
US10551832B2 (en) 2017-08-29 2020-02-04 Cnh Industrial America Llc Method and system for transporting an autonomous agricultural vehicle
WO2023167878A1 (en) 2022-03-01 2023-09-07 Altin Biosciences Corporation Crila® and egcg compositions for treatment of fibroids

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2882287A (en) * 1954-08-30 1959-04-14 Air Reduction Methylbutynyl stearate
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
DE1543749A1 (de) * 1966-02-16 1969-12-11 Merck Ag E Verfahren zur Herstellung von 3,4-cis-4-Aryl-isoflavanen
US3822287A (en) * 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3882287A (en) * 1973-04-20 1975-05-06 Perkins Res & Mfg Co Method and apparatus for detecting faults and locating conductors in multi-conductor cables
US4302453A (en) * 1979-11-13 1981-11-24 E. R. Squibb & Sons, Inc. Antiarrhythmic tetrahydronaphthalene derivatives
US4447622A (en) * 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
IT1205124B (it) * 1987-06-05 1989-03-15 Simens Soteta Italiana Medicin Composto attivo nella terapia carciovascolare
US4988755A (en) * 1987-12-14 1991-01-29 The B. F. Goodrich Company Passivated rare earth magnet or magnetic material compositions
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5446061A (en) * 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5407947A (en) * 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) * 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease
HUP9800521A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or propylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis

Also Published As

Publication number Publication date
US5843976A (en) 1998-12-01
US5407955A (en) 1995-04-18
US5962497A (en) 1999-10-05
US6011057A (en) 2000-01-04
DE69513708D1 (de) 2000-01-13
CA2142513A1 (en) 1995-08-19
US5453442A (en) 1995-09-26
EP0672412A2 (de) 1995-09-20
US5977157A (en) 1999-11-02
JPH07258080A (ja) 1995-10-09
US5952364A (en) 1999-09-14
DE69513708T2 (de) 2000-06-21
EP0976398A3 (de) 2000-11-15
EP0672412B1 (de) 1999-12-08
US6025381A (en) 2000-02-15
EP0976398A2 (de) 2000-02-02
US5482958A (en) 1996-01-09
ES2140618T3 (es) 2000-03-01
GR3032813T3 (en) 2000-06-30
DK0672412T3 (da) 2000-04-17
EP0672412A3 (de) 1995-12-27
PT672412E (pt) 2000-05-31
US5472977A (en) 1995-12-05

Similar Documents

Publication Publication Date Title
ATE187330T1 (de) Verwendung von 3,4-diphenyl chroman derivaten zur herstellung eines medikaments zur absinkung des cholesterolspiegels
DE69332735D1 (de) Verwendung von Benzothiophene zur Behandlung von Hypercholesterolämie
AU8155894A (en) Methods of inhibiting thrombin
ATE205206T1 (de) Benzylidenthiazolidinderivate, ihre herstellung und ihre anwendung als lipidperoxid-inhibitoren
DE69426855D1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung des Knorpelabbaus
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
DE69710326T2 (de) Verwendung eines toremifenemetaboliten zur senkung des serumcholesterinspiegels
ATE220323T1 (de) Methode zur behandlung von resistenten neoplasmen
DE59409248D1 (de) Verwendung von Phenalkylaminen zur Herstellung von cholesterinsenkenden Arzneimitteln
DE69420679D1 (de) Verwendung der 1-4-4-Aryl(oder Heteroaryl)-1-Piperazinylbutyl-1H-Azol-Derivate zur Herstellung von Arzneimitteln zur Behandlung der Störungen der Magensekretion
ATE121395T1 (de) Cumarinderivate, ihre herstellung und ihre verwendung zur behandlung von zerebrovaskulären störungen.
EP1275390A3 (de) Arzneimittel zur Behandlung der Herzinsuffizienz
DE50013571D1 (de) Arzneimittel zur behandlung von neuropathien
DE69426316T2 (de) Verwendung von Beta-Naphthochinonderivaten zur Beschleunigung der Proliferation der Endothelzellen und Inhibierung der NO-Synthasen
ATE97573T1 (de) Verwendung von steroiden als antipilzmittel.
KR900001367A (ko) 폐의 폐색성 기능장애 및/또는 출뇨관 기능장애 치료용 약제로서 치환된 3,4-디하이드로-2h-벤조피란의 용도
NZ296285A (en) Inhibiting physiological conditions associated with bradykinin using a benzothiophene such as raloxifene
IE842555L (en) Aroylalkanamines
EP1245564A4 (de) Benzamidinderivate
ATE169012T1 (de) Aminoalkylsubstituierte thiazolin-2-one, ihre herstellung und verwendung
ATE142501T1 (de) Verwendung von 1-(beta-d-arabinofuranosyl)-5- propynyluracil zur senkung des serumcholesterins
ATE192155T1 (de) Tetracyclische 1,4-oxazin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE69509657D1 (de) Verwendung von benzothiophenen zur herstellung eines medikaments zur verminderung der narbenbildung bei der wundheilung
DE69426317D1 (de) Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation
DE69109072D1 (de) Aminoalkylketonderivate, Verfahren zu ihrer Herstellung und ihre therapeutischen Anwendungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee